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RESUME EN FRANÇAIS 
BUTS. Etudier les relations entre le diabète gestationnel (GDM) et le syndrome 
métabolique (MS), comme la résistance à l'insuline est une des caractéristiques des 
deux conditions. Analyser le dépistage du diabète dans le post-partum pour identifier 
les facteurs de risque associés au développement d'un diabète de type 2 ultérieur. 
METHODES. Etude rétrospective de toutes les grossesses uniques diagnostiquées 
avec un diabète gestationnel à l'hôpital universitaire de Lausanne, pendant une 
durée de trois ans. La présence d'une obésité, d'une hypertension ou d'une 
dyslipidémie avant la grossesse définissent les composants du syndrome 
métabolique. 
RESULTATS. Sur 5788 grossesses, 159 patientes (2.7%) présentaient un diabète 
gestationnel. Des composants du syndrome métabolique étaient présents avant la 
grossesse chez 26% des patientes (n=37/144): 84% (n=31/37) étaient obèses, 38% 
(n=14/37) présentaient une hypertension et 22% (n=8/37) une dyslipidémie. Le 
développement d'une hypertension gravidique était associé à l'obésité (OR=3.2, 
p=0.02) et à la dyslipidémie (OR=5.4, p=0.002). Septante-quatre patientes (47%) 
sont revenues pour l'HGPO dans le post-partum. Celle-ci était anormale chez 20 
femmes (27%): 11 % (n=8) présentaient un diabète de type 2 et 16% (n=12) avaient 
une intolérance au glucose. Les facteurs de risque indépendants associés à une 
anomalie de la tolérance au glucose dans le post-partum étaient d'avoir plus de 2 
valeurs anormales au test diagnostique durant la grossesse et présenter des 
composants du syndrome métabolique (OR=5.2, Cl 1.8-23.2 et OR=5.3, Cl 1.3-22.2). 
CONCLUSIONS. Dans un quart des grossesses avec un diabète gestationnel, des 
anomalies métaboliques précèdent l'apparition de l'intolérance au glucose. Ces 
patientes présentent un haut risque de développer un syndrome métabolique et un 
diabète de type 2 ultérieurement. Là où le dépistage du diabète gestationnel n'est 
pas systématique, les praticiens devraient être avertis de ces risques métaboliques 
chez les patiente se présentant avec une obésité, une hypertension ou une 
dyslipidémie, afin de mieux les diagnostiquer et surtout de mieux les suivre et traiter 
après leur grossesse. 
Il ORIGINAL ARTICLE 
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SUMMARY 
Aims: Ta investigate the relationships between gestational diabetes 
mellitus (GDM) and the metabolic syndrome (MS), as it was sug-
gested that insulin resistance was the hallmark of bath conditions. Ta 
analyse post-partum screening in order ta identify risk factors for the 
subsequent development of type 2 diabetes mellitus (DM). 
Methods: A retrospective analysis of all singleton pregnancies diag-
nosed with GDM at the Lausanne University Hospital for 3 consecu-
tive years. Pre-pregnancy obesity, hypertension and dyslipidaemia 
were recorded as constituents of the MS. 
Results: For 5788 deliveries, 159 women (2.7%) with GDM were 
identified. Constituents of the MS were present before GDM preg-
nancy in 26% (n = 37/144): 84% (n = 31/37) were obese, 38% 
(n = 14/37) had hypertension and 22% (n = 8/37) had dyslipidaemia. 
Gestational hypertension was associated with obesity (OR = 3.2, 
P = 0.02) and dyslipidaemia (OR= 5.4, P = 0.002). Seventy-four 
women (47%) returned for post-partum OGTT, which was abnormal 
in 20 women (27%): 11 % (n = 8) had type 2 diabetes and 16% 
(n = 12) had impaired glucose tolerance. lndependent predictors 
of abnormal glucose tolerance in the post-partum were: having 
> 2 abnormal values on the diagnostic OGTT during pregnancy and 
presenting MS constituents (OR = 5.2, Cl 1.8-23.2 and OR = 5.3, 
Cl 1.3-22.2). 
Conclusions: ln one fourth of GDM pregnancies, metabolic abnor-
malities precede the appearance of glucose intolerance. These 
women have a high risk of developing the MS and type 2 diabetes in 
later years. Where GDM screening is not universal, practitioners 
should be aware of those metabolic risks in every pregnant woman 
presenting with obesity, hypertension or dyslipidaemia, in order ta 
achieve better diagnosis and especially better post-partum follow-up 
and treatment. 
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RÉSUMÉ 
Le diabète gestationnel et le risque de syndrome 
métabolique ; une étude de population à Lausanne, 
Suisse 
Buts: Étudier les relations entre le diabète gestationnel (GDM) et le 
syndrome métabolique (MS), car la résistance à l'insuline est une 
des caractéristiques des deux conditions. Analyser le dépistage du 
diabète dans le post-partum pour identifier les facteurs de risque 
associés au développement d'un diabète de type 2 ultérieur. 
Méthodes: Éude rétrospective de toutes les grossesses uniques dia-
gnostiquées avec un diabète gestationnel à l'hôpital universitaire de 
Lausanne, pendant une durée de trois ans. La présence d'une obé-
sité, d'une hypertension ou d'une dyslipidémie avant la grossesse 
définissent les composants du syndrome métabolique. 
Résultats: Sur 5788 grossesses, 159 patientes (2,7 %) présentaient un 
diabète gestationnel. Des composants du syndrome métabolique étaient 
présents avant la grossesse chez 26 % des patientes (n = 37/144): 
84 % (n = 31/37) étaient obèses, 38 % (n = 14/37) présentaient une 
l1ypertension et 22% (n = 8/37) une dyslipidémie. Le développement 
d'une hypertension gravidique était associé à l'obésité (OR= 3,2, 
P = 0,02) et à la dyslipidémie (OR = 5,4, P = 0.002). Soixante-qua-
torze patientes (47 %) sont revenues pour l'HGPO dans le post-par-
tum. Celle-ci était anormale chez 20 femmes (27 % ) ; 11 % (n = 8) 
présentaient un diabète de type 2 et 16 % (n = 12) avaient une intolé-
rance au glucose. Les facteurs de risque indépendants associés à 
une anomalie de la tolérance au glucose dans le post-partum étaient 
d'avoir plus de 2 valeurs anormales au test diagnostique durant la 
grossesse et présenter des composants du syndrome métabolique 
(OR = 5,2, Cl 1,8-23,2 et OR = 5,3, Cl 1,3-22,2). 
Conclusions : Dans un quart des grossesses avec un diabète gesta-
tionnel, des anomalies métaboliques précèdent l'apparition de l'into-
lérance au glucose. Ces patientes présentent un haut risque de 
développer un syndrome métabolique et un diabète de type 2 ulté-
rieurement. Là où le dépistage du diabète gestationnel n'est pas sys-
tématique, les praticiens devraient être avertis de ces risques 
métaboliques chez les patientes se présentant avec une obésité, une 
hypertension ou une dyslipidémie, afin de mieux les diagnostiquer et 
surtout de mieux les suivre et traiter après leur grossesse. 
Mots-clés: Diabète gestationnel · Syndrome métabolique· 
Intolérance au glucose dans le post-partum · Diabète de type 2 dans 
le post-partum. 
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Introduction 
Gestational diabetes mellitus (GDM) is defined as 
varying degrees of carbohydrate intolerance with onset or 
first recognition during pregnancy [l, 2 J. Its prevalence 
varies between 1 and 14%, depending on the populations 
studied and the criteria used for diagnosis [2 J. GDM is 
frequently associated with adverse pregnancy outcomes 
[l, 3, 4]. Prevention of macrosomia and perinatal complica-
tions are prirnary goals in the treatment of wornen with 
pregnancies complicated by GDM. 
It has long been known that women with a history of 
GDM are at increased risk of developing type 2 diabetes 
mellitus (type 2 DM) later in life, and this was originally 
the purpose of identifying GDM [5]. Long-term follow-up 
studies indicate a conversion rate to type 2 diabetes 
between 10 and 50% [6J. Likewise, recent studies have 
shown that GDM also increases the risk of long-term 
development of hypertension and dyslipidaemia, and 
therefore also atherosclerosis and coronary heart disease 
[7, 8J. The frequently recognized association between glu-
cose intolerance, obesity, hypertension and dyslipidaemia 
has led to the recognition of what is now known as the 
rnetabolic syndrome (MS). The major adverse conse-
quence of the MS is cardiovascular disease (CVD), as sev-
eral of its constituent metabolic abnormalities are in fact 
CVD risk factors. Insulin resistance is considered a central 
pathophysiological process both behind the metabolic syn-
drome and the development of gestational diabetes melli-
tus [8, 9]. Indeed several groups have hypothesized that 
GDM may be one of the first metabolic abnormalities to be 
recognized in the development of the metabolic syndrome 
[8, 10, 11]. Recently, two groups have also shown that the 
metabolic syndrome increases the risk for diabetes inde-
pendently of other risk factors, including glycaemia or 
insulin measurements [12, 13]. 
Results from diabetes prevention studies have shown 
that lifestyle modifications and/or treatment with oral anti-
diabetics can reduce the incidence of diabetes in individuals 
with impaired glucose tolerance (IGT) and in other high-
risk populations [14-16]. Because of these positive results, it 
has become more relevant to identify subjects at risk for 
diabetes. Women diagnosed with GDM make up one of 
those high-risk populations. It is therefore of critical irnpor-
tance both that they are diagnosed during pregnancy and 
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that they have a regular and long-term post-partum follow-
up, to allow for the identification and the treatment of any 
persistent metabolic abnormality. 
The first purpose of our study was to analyse the popu-
lation characteristics of pregnant women with GDM in 
relation to the metabolic syndrome constituents. Our sec-
ond aim was to evaluate the post-partum results and the 
identification of the risk factors associated with post-par-
tum impaired glucose tolerance and type 2 diabetes. 
Methods 
Patients 
We conducted a retrospective analysis of all singleton 
pregnancies diagnosed with GDM between January 2000 
and December 2002 at the Lausanne University Hospital. 
The patients were identified by the GDM diagnosis listed 
on the medical record of the delivery. Medical history, phy-
sical examination and laboratory values were then ob.tained 
by reviewing the hospital medical records of the obstetric 
and diabetic outpatient clinics. We excluded from the study 
ail patients with pre-existent type 1 or type 2 diabetes. 
Diagnosis of GDM 
During pregnancy follow-up, gynaecologists at the obs-
tetric outpatient clinic use the following risk factors to 
screen women for GDM: a first degree relative with diabe-
tes, a history of GDM or macrosomia, a suspicion of macro-
somia in the current pregnancy, persistent glucosuria, a 
rapid or excessive weight gain during early pregnancy, obe-
sity, or a random plasma glucose :2: 7.0 mmol/l. Women 
with one or more of these factors underwent the standard 
100 g 3-h oral glucose tolerance test (OGTT) after an over-
night fast. The diagnosis of GDM was made according to 
the National Diabetes Data Group (NDDG) criteria (:2: 2 
abnormal values; glucose concentrations of::O: 5.8 mmol/l for 
fasting, :2: 10.6 mmol/l at 1 hour, :2: 9.2 mmol/l at 2 hours, 
and :2: 8.1 mrnol/l at 3 hours) Jl 7]. The glucose values for 
the OGTT were all measured by the central laboratory of 
the University Hospital. 
Metabolic syndrome (MS) 
Both the WHO and the National Cholesterol Educa-
tion Program (NCEP) have proposed extensive definitions 
of the metabolic syndrorne [ 18, 19]. These definitions are 
however not usually applied in the clinicat setting of an 
obstetric outpatient clinic. Furthermore, as microalbu-
minuria and insulin values are not routinely measured, we 
used our own definition, based on the data actually 
recorded by the gynaecologists at the first antenatal visit, 
to remain as close as possible to the proposed definitions. 
We considered that a GDM diagnosis was a marker of an 
jnsulin-resistant state and therefore comparable to the 
{mpaired glucose tolerance (IGT) diagnosis. We thus iden-
tified the MS in women with IGT defined by their GDM 
diagnosis and at least one of the following factors: hyper-
tension, dyslipidaemia and/or obesity. The tertTl metabolic 
syndrome (MS) used in the results refers to this particular 
definition, keeping in mind that it does not completely 
correspond to the definitions given by the WHO or the 
NCEP. Hypertension was diagnosed if the patient was 
receiving antihypertensive clrugs before her pregnancy 
and/or if bloocl pressure was higher than 140/90 mmHg at 
the first antenatal visit, in accordance with the obstetric 
criteria. Dyslipidaemia was recognized if the woman was 
taking a hypolipaemic treatment before her pregnancy. 
Obesity was present if the pre-pregnancy body mass index 
(BMI) was :2: 30 kg/m2• 
Pregnancy and post-partum follow-up 
Women with GDM were regularly seen during their 
pregnancy by a team composed of a diabetologist, a trained 
dietician and a diabetes nurse. They were managed initially 
with self-monitoring of blood glucose 4-6 tin1es daily and 
clietary measures. The therapeutic aims were blood glucose 
levels before meals < 5.0 mmol/l and 2 hour postprandial 
< 6.5 mmol/l. If two blood glucose levels in one to two 
weeks were above these aims clespite adequate dietary 
measures, insulin of the rapicl type was startecl or doses 
were increased. If these measures were insufficient to reach 
the therapeutic aims, a basal insulin was added [2J. During 
pregnancy maternai complications were diagnosed as: 
oedema, proteinuria on dipstick test, gestational hyperten-
sion and pre-eclampsia. These complications were clefinecl 
and recorclecl at the Obstetric Outpatient Unit. Gestational 
hypertension was defined as the development of a bloocl 
pressure :2: 140/90 mmHg during pregnancy. Pre-eclan1psia 
was clefined as bloocl pressure :2: 140/90 mmHg combined 
with proteinuria on dipstick test. 
Diet and insulin therapy were discontinued after 
delivery. On the second post-partum day, a fasting plasma 
glucose (FPG) value was measured in ail women. Recom-
mendation was given to ail the patients that they should 
unclergo a postnatal test with the WHO 2-h 75 g glucose 
challenge test 8 weeks after clelivery [2, 18]. The cliagnosis 
of post-partum diabetes was made according to the World 
Health Organization criteria [18]. 
Statistical analyses 
Continuous variables normally distributed were 
expressed in means ±standard cleviation (SD) and were 
compared using the unpairecl Student's t test. Non-nor-
mally clistributed continuous variables were expressecl in 
meclian, PlO - P90 interval and Mann-Whitney U test was 
used for correlation. Categorical variables were expressed 
in frequency and differences were based on the chi-square 
Gestational diabetes mellitus and metabolic syndrome 
test. For several analyses we used a fasting plasma glucose 
thresholcl of 5.6 mmol/l based on the new criteria for fasting 
plasma glucose recommenclecl by the Expert Committee on 
the diagnosis and classification of Diabetes Mellitus in 
November 2003 [20]. Forward stepwise logistic regression 
analyses were performed with Stata 8.0 (Stata Corporation, 
College Station, TX, USA); all other statistical analyses 
were perforrned using JMP 5.0 (SAS Institute, Cary, USA). 
A P value~ 0.05 was consiclered statistically significant. 
Results 
Diagnosis and investigation of GDM 
For the 3-year study period, there were 5788 deliveries at 
the Obstetric ward. A total of 159 women were cliagnosed 
with GDM during that time, their characteristics are pre-
sented in Table I. The calculatecl prevalence of GDM was 
2.7%. The 100 g 3-h OGTT test results were available for 
89% of the patients (n = 141). Eighteen women coule! not 
complete the OGTT because of nausea and/or vomiting. 
We therefore recorded only the fasting plasma glucose. To 
make the cliagnosis, these women were followecl with self-
monitoring of blood glucose 4-6 times daily over one week, 
and if the bloocl glucose levels before meals were repeatedly 
> 5.0 mmol/l and/or 2 hour postprandial > 6.5 mmol/l, we 
consiclerecl thern to have GDM and treatecl them as the oth-
ers. We cannot give the respective frequencies of the factors 
usecl for screening, because they were not recorclecl specifi-
cally for each woman. The median gestational age at GDM 
Table 1 
Population characteristics (n = 159). 
Age at diagnosis (y) 
Caucasian origin 
Pre-pregnancy weight (kg) 
Pre-pregnancy BMI (kg/m2) 
Obesity (BMI ~ 30 kg/m2) 
Parity ~ 1 
History of macrosomia 
History of GDM 
Familial history of diabetes mellitus 
Familial history of obesity 
Familial history of CVD 
Hypertension 
Dyslipidaemia 1 
Metabolic syndrome 
GDM population (n = 159) 
33 ± 5 
62% 
68±14 
25.9 ± 5.1 
22% 
61% 
40% 
26% 
47% 
13% 
29% 
9% 
5% 
26% 
BMI: body mass index; CVD: cardiovascular disease. 
1 We only have information for 108 (68%) patients. 
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diagnosis was 28 (21-34) gestational weeks (GW). Forty-two 
percent of the women (n = 60) had the OGTT after the rec-
ommended 24-28 GW interval [2J. Median HbA1c recorded 
at diagnosis was 5.4 (4.7-6.6)%. The eut-off HbA1c ~ 5.4% 
was used for further analyses. 
Metabolic syndrome and its consequences 
during pregnancy 
In our GDM population, the total prevalence of the 
metabolic syndrome before pregnancy was 26% (n = 37/144), 
which means that one woman in 4 had metabolic abnorma-
lities. Among the constituents of the MS, obesity was pre-
sent in 84% (n = 31/37), hypertension in 38% (n = 14/37) 
and dyslipidaemia in 22% (n = 8/37). Moreover obesity was 
significantly associated with pre-existent hypertension 
(OR= 5.1, P < 0.001), dyslipidaemia (OR= 2.9, P = 0.02) 
and with insulin therapy need during pregnancy (OR = 2.7, 
P = 0.003). Lipid profiles were measured only in 68% of the 
patients (n = 108/159), which might indicate that we are 
under-estimating the true prevalence of dyslipidaemia. 
The patients were divided according to their ethnie 
background in 4 groups and the metabolic abnormalities 
within each group are presented in Table II. Sixty-two per-
cent were Caucasians from European countries (n = 98), 
12% were Asian Indians mostly from Sri Lanka (n = 19), 
13% came from North Africa and the Middle East (n = 20) 
and 14% represented several other African and Asian coun-
tries (n = 22). The groups were not large enough to gain 
significant statistical power. 
The MS was strongly correlated with several maternai 
complications. These were recorded as follows: oedema 
(48%), proteinuria on dipstick test (32%), gestational hyper-
tension (11 %) and pre-eclampsia (5%). The presence of the 
MS before the onset of pregnancy was an important risk 
factor for the development of gestational hypertension 
(OR= 5.1, P = 0.001). Results are presented in Table III. 
Pre-eclampsia on the other hand was only correlated with a 
FPG ~ 5.6 mmol/l on the OGTT (OR= 4.5, P = 0.04), but 
not with other metabolic disturbances such as obesity, 
hypertension or dyslipidaemia. 
Table Il 
Pre-pregnancy metabolic syndrome constituents in different ethnie 
groups (n = 159). 
Caucasians Asian North Olhers 
{n = 98) lndians Africans {n = 22) 
{n = 19) {n = 20) 
Obesity 19% 5% 25% 27% 
Hypertension 7% 0 15% 18% 
Dyslipidaemia 6% 5% 5% 0 
The differences were ail non-significant. 
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Table Ill 
Maternai complications (n = 135). 
No MS With MS OR p 
(n = 100) {n = 35) 
Age 32.3 ± 0.45 33.6 ± 0.78 0.1 
Oedema 46% 66% 1.8 0.05 
Proteinuria 26% 49% 2.0 0.01 
Pre-eclampsia 4% 9% 1.7 0.3 
(n = 100) (n = 21) 
Gestational 6% 30% 3.7 0.001 
hypertension 
Gestational hypertension is defined as the new development of 
hypertension during pregnancy, and thus we did not include the 
14 patients with pre-existent hypertension in the analysis. 
Insulin treatment during pregnancy 
At the time of delivery, 60% of the women (n = 96) were 
treated with insulin. Twenty-eight percent (n = 27) were 
treated only with rapid insulin, 10% (n = 10) only with 
basal insulin and 61 % (n = 59) with both. The median doses 
recorded at delivery were: rapid insulin 16 (6-44) units and 
basal insulin 14 (8-50) units. Table IV shows the factors pre-
dicting basal insulin need: obesity, hypertension, high gly-
caemic values, early GDM diagnosis and multiparity. 
Forward stepwise logistic regression analysis confirmed 
FPG ~ 5.6 mmol/l (OR = 11.6, CI 3.5-37.9), a GDM dia-
gnosis made before 28 GW (OR= 3.0, CI 1.1-8.2) and mul-
tiparity (OR = 3.3, CI 1.2-9.4) to be significant independent 
risk factors for basal insulin treatment during pregnancy. 
Post-partum population 
After an average of 9.5 (6.4-45.0) weeks, 47% of the 
mothers (n = 74) returned for the post-partum 75 g OGTT. 
Table IV 
Factors predicting basal insulin need (n = 159). 
No insu lin Basal insu lin OR p 
need need 
{n=90) {n=69) 
FPG <': 5.6 mmol/1 17% 57% 2.5 < 0.001 
Pre-pregnancy 3% 15% 1.9 0.01 
hypertension 
Pre-pregnancy obesity 12% 33% 1.8 0.003 
GA at diagnosis 34% 57% 1.7 0.004 
< 28 weeks 
HbA1c è: 5.4% 45% 69% 1.7 0.01 
Parity <': 1 53% 72% 1.6 0.02 
GA: gestational age. 
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Table V shows that the population characteristics of the 
patients that came for post-partum testing were similar to 
those that did not corne. A few points were nonetheless 
interesting. The women who underwent an OGTT during 
pregnancy were 9 times more likely to corne back after deli-
very to tak.e a second test (OR= 8.8, P < 0.001). Likewise, 
women who were treated with insulin during their pre-
gnancy also returned more frequently for follow-up 
(OR = 1.9, P = 0.001). 
Post-partum OGTT results 
Results are shown in figure 1. A total of 8 women (11 %) 
had a diagnosis of type 2 diabetes mellitus, and 12 patients 
(16%) had impaired glucose tolerance. Of these, three (25%) 
also had impaired fasting glucose (FPG ~ 6.1 mmol/l). 
These 20 patients were collectively identified as having 
abnormal glucose tolerance (AGT) and were analysed as 
one group. There were interesting but non-significant eth-
nie differences: among Asian Indians 70% returned for 
post-partum testing and 38% had AGT, compared to 46% of 
Caucasians who returned of which 20% had AGT and only 
35% of North Africans took the OGTT and 14% had AGT. 
Factors predicting post-partum AGT in univariate 
analysis are presented in Table VI. These variables can be 
divided into two main groups: those concerning glycaemic 
values (high FPG at diagnosis of GDM, > 2 abnormal val-
ues on the OGTT, HbA 1c and rd post-partum day FPG) 
and those associated with the MS (pre-pregnancy BMI, dys-
lipidaemia and gestational hypertension). In forward step-
Table V 
Population characteristics at diagnosis (n = 159). 
Gestational diabetes mellitus and metabolic syndrome 
74 women returned for the post-partum OGTT 1 
. ~ 
12 women had 8 women had 
impaired Glucose type 2 diabetes 
Tolerance (16%) mellitus (11 % ) 
/ 
20 women had abnormal 
Glucose Tolerance (27%) 
Caucasians (n=45) 
20% had AGT (n=9) 
Asian lndians (n=13) North Africans (n=7) 
38% had AGT (n=5) 14% had AGT (n=1) 
lmpaired Glucose Tolerance: 2-h postprandial glucose 7.8-11.0 mmol/I 
Type 2 diabetes mellitus: FPG 2 7 .0 mmol/I 
or2-h postprandial glucosez 11.1 mmol/I 
Figure 1 
The results of the post-partum Oral Glucose Tolerance Test (OGTT). 
wise logistic regression analysis two independent predictors 
were identified: the metabolic syndrome (OR = 5.3, CI 1.3-
22.2) and > 2 abnormal values on the OGTT (OR = 5.2, 
CI 1.8-23.2). 
No post-partum follow-up Post-parfum follow-up OR p 
{n = 85) (n = 74) 
Age at diagnosis (y) 33 33 0.9 
Caucasian origin 54% 51% 0.9 0.7 
Pre-pregnancy weight (kg) 68 67 0.8 
Pre-pregnancy BMI (kg/m2) 25.9 25.1 0.9 
Obesity (BMI è: 30 kg/m2) 21% 23% 1.1 0.7 
Parity <': 1 57% 66% 1.2 0.3 
History of macrosomia 48% 33% 0.7 0.15 
History of GDM 28% 24% 0.9 0.7 
Familial history of diabetes mellitus 48% 47% 1.0 0.9 
Familial history of obesity 14% 13% 1.0 0.9 
Familial history of CVD 26% 32% 1.2 0.4 
Hypertension 13% 4% 0.4 0.05 
Dyslipidaemia 7% 3% 0.5 0.2 
Metabolic syndrome 27% 24% 0.9 0.7 
Took the 1 OOg OGTT 81% 99% 8.8 < 0.001 
Were treated with insulin 49% 75% 1.9 0.001 
BMI: body mass index; CVD: cardiovascular disease; NS: non-significant. 
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Table VI 
Factors predicting post-partum abnormal glucose tolerance (n = 74). 
Normal GT (n = 54) Abnormal GT (n = 20) OR p 
Glycaemic values: 
HbA1c2: 5.4% 
FPG at OGTT :::o: 5.3 mmol/I 
> 2 abnormal values on the OGTT 
Post-partum FPG :::o: 5.6 mmol/I 
Metabolic parameters: 
Pre-pregnancy 
dyslipidaemia 
Metabolic syndrome 
Pre-pregnancy obesity 
Gestational hypertension 
GT: glucose tolerance. 
Figure 2 shows the Receiver Operator Characteristic 
(ROC) curve for AGT by fasting plasma glucose at OGTT 
during pregnancy. The area under the curve (AUC) is 0.812 
and P < 0.0001, demonstrating the highly discriminative 
power of FPG in predicting post-partum AGT. The FPG 
value closest to the ideal of 100% sensitivity and 100% spe-
cificity was 5.3 mmol/l. This eut-off was 88% sensitive and 
70% specific. As illustrated in figure 3, the concomitant 
presence of metabolic syndrome constituents before preg-
Sensitivily (!rue positive) 
1 
0.9 
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0.7 
0.6 
0.5 
0.4 
0.3 
0.2 
0.1 
0 
ç:i 
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r;:ri 
r 
9 
9 
6 
0.2 0.4 
No Discrimination 
··-Ü"' FPG at OGTT 
AUC = 0.812 
p < 0.0001 
0.6 0.8 
1 - Specificily (false positives) 
Figure 2 
ROC curve for the occurrence of post-partum Abnormal Glucose 
Tolerance by OGTT lasting plasma glucose (FPG) du ring pregnancy. 
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45% 94% 10.7 0.001 
38% 85% 5.5 < 0.001 
33% 81% 5.3 0.001 
7% 55% 4.8 < 0.001 
3% 13% 4.0 0.02 
16% 50% 3.1 0.006 
16% 44% 2.6 0.02 
6% 21% 2.3 0.07 
nancy and a FPG ::'.'. 5.6 m.mol/l at GDM diagnosis increased 
the prevalence of post-partum AGT to 78% compared to 
the 10% in women with no metabolic disturbances 
(OR= 7.6, P < 0.001). 
After the post-partum OGTT, ail wornen with AGT 
continued to be followed at the diabetic outpatient clinic. 
Thirteen (65%) were managed only with nutritional advice, 
whereas 4 (20%) were started on oral antidiabetic drugs and 
3 (15%) needed to restart insulin therapy. 
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Figure 3 
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Prevalence of abnormal glucose tolerance (AGT) in function of the presence 
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piscussion 
Severa! studies have examined the development of the 
metabolic syndrome in parous women and suggested that a 
history of GDM in a previous pregnancy was an important 
risk factor [8, 10]. They have also postulated that GDM 
might be considered an early expression of the metabolic 
syndrome. In our study we analysed the pre-pregnancy 
presence of obesity, hypertension and dyslipidaernia in 
women with GDM and their influence on the subsequent 
development of impaired glucose tolerance and type 2 DM. 
The importance of these issues is emphasized by the contin-
uous increase in the prevalence of obesity, diabetes, hyper-
tension and other obesity related health risk factors in the 
Western world [21, 22]. 
The main findings of our study were the important 
prevalence of metabolic syndrome constituents present in 
women before their GDM pregnancy and the associated 
increased risk of future type 2 DM, as measured in the post-
partum. Indeed, 26% of the patients presented rnetabolic 
abnormalities before their GDM pregnancy, mostly obesity 
in 84% of them. These metabolic abnormalities were inde-
pendently associated with a 5-fold increase in the risk of 
developing an abnormal glucose tolerance in the close post-
partum. 
An interesting point to note concerned the timing of 
the diagnostic OGTT during pregnancy. Forty-two per-
cent of the patients with risk factors for GDM were tested 
after the recommended 24-28 GW. As stated before, there 
is no consensus on the screening strategy of GDM and our 
patients were taken up in the study by the means of their 
obstetric diagnosis. Gynaecologists might be Jess sensitive 
to the importance of the metabolic syndrome and its con-
sequences and this is a fact that we tried to improve with 
this study. 
Among our GDM population, 22% of the women pre-
sented pre-pregnancy obesity and 9% had hypertension. 
Blood pressure, lipid profiles and height were not systemat-
ically measured in pregnant women without GDM and we 
were thus unable to compare the prevalence of these fac-
tors. An interesting point to note, although not significant, 
was the distribution of obesity among different ethnie 
groups. The lowest prevalence of obesity was found in 
Asian Indians (5%), followed by Caucasians (18%) and was 
highest in North Africans (25%). In our study, Asian Indi-
ans showed a high degree of abnormal glucose tolerance in 
the post-partum. This could in part be explained by their 
high compliance (70% returned for the post-partum test), 
but may also support the knovvn fact that even without 
being overweight they have a high degree of insulin resist-
ance, because of adverse upper body adiposity [23, 24]. 
Obesity is a simple criterion recommended by the WHO 
for non-systematic screening of GDM and gynaecologists 
use it to guide their screening because obesity is also associ-
ated with other obstetric complications. Of course, this 
Gestational diabetes mellitus and metabolic syndrome 
could also act as a screening bias and explain the high prev-
alence of obesity among our GDM patients. Obesity was 
moreover significantly associated with hypertension, dysli-
pidaemia and increased insulin need during pregnancy, 
emphasizing the interdependence of these parameters 125]. 
Insulin therapy was further associated with a GDM diagno-
sis before 28 gestational weeks, high fasting plasma glucose 
on the OGTT and multiparity, ail three markers of serious 
disturbances in carbohydrate metabolism 14, 26, 27]. We can 
thus postulate that in this subgroup of women the insulin 
resistance was already present before the current preg-
nancy. The metabolic burden of pregnancy led to a progres-
sion of the insulin resistance and its clinical complications. 
Indeed, the additional raie of the placenta! hormones in the 
development and accentuation of insulin resistance, even in 
non-diabetic women, is well established l28j. These women 
also had most of the risk factors for post-partum abnormal 
glucose tolerance, namely components of the metabolic syn-
drome, and high glycaemic values at diagnosis and in the 
immediate post-partum days. The risk of AGT was 
increased 7-fold compared to patients without these crite-
ria. This suggests that these factors act synergistically to 
produce adverse metabolic outcomes. 
In most women luckily, the insulin resistance decreases 
after delivery and the glucose intolerance disappears. These 
women can be considered to have more subtle metabolic 
disturbances than the patients presenting with constituents 
of the metabolic syndrome before their pregnancy. How-
ever, as known from many studies, ail women with a his-
tory of GDM are at increased risk for the future 
development ofIGT and type 2 DM [6, 27, 29]. Thus, these 
women have a lower resilience to the metabolic challenges 
of pregnancy because they eventually have a decreased pan-
creatic beta-cell fonction reserve [29]. One central patho-
genic mechanism has been shown to be the progression of 
insulin resistance, together with endothelial dysfonction 
and low-grade inflammation [30, 31]. Even in the absence 
of pre-pregnancy obesity, women with a history of GDM 
have an almost 5-fold additional independent risk of devel-
oping the rnetabolic syndrome compared to contrais with-
out GDM [10]. Winzer et al. showed that women with 
prior GDM had reduced adiponectin concentrations inde-
pendently of obesity and metabolic abnormalities and this 
was associated with sub-clinical inflammation and athero-
genic parameters [31]. The important consequence of this 
relationship is the greatly increased risk of cardiovascular 
disease in patients with the metabolic syndrome [32-34]. 
Different studies have shown that with appropriate life-
style modifications (diet, regular exercise) or glitazone 
treatment the ~-ce!! fonction can be preserved and this in 
turn reduces the progression to type 2 DM in high-risk 
populations, for example in women with a previous GDM 
pregnancy f 14-16]. In view of the serious metabolic and 
clinical complications of the metabolic syndrome and the 
new possibility to delay their appearance, it is of particular 
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importance to regularly follow these women after their 
pregnancy. The risk of developing impaired glucose toler-
ance and type 2 DM should be assessed by an oral glucose 
challenge test or a fasting plasma glucose measurement, as 
recommended by many guidelines [2, 18, 35]. 
Severa\ limitations to our study need to be mentioned. 
As this was a retrospective study and that at the time of the 
study the patients were not systematically summoned after 
their delivery to take the post-partum OGTT, many 
women were lost to follow-up, and we cannot increase this 
percentage for the present study. Secondly, there are several 
points in which the patients that participated in the post-
partum follow-up differ from the others, and th us our post-
partum population might not be entirely representative of 
the total population. Interestingly, women that underwent 
an OGTT during pregnancy were 9 times more likely to 
corne back after delivery, likely because they already knew 
what was to be expected from the procedure. Insulin treat-
ment also prompted women to corne back, as mentioned in 
other studies [27]. Complying with an intensive treatment 
during their pregnancy might have increased those 
patients' awareness of the importance and risks attached to 
these metabolic abnormalities. But it could also bias our 
results towards glucose intolerance. The participation rate 
also differed among ethnie groups and this bias could be 
related to insulin treatment: 40% of Caucasians needed 
insulin treatment, only 32% of North Africans but 58% of 
Asian Indians. Thus, if Asian Indians needed insulin treat-
ment more frequently, it could also explain their overrepre-
sentation at follow-up. Yet, for ail other parameters, the 
two groups were quite similar in pre-pregnancy variables. 
In a systematic review, Kim et al. showed very variable 
retention rates (38%-100%) for post-partum follow-up, sug-
gesting that this is a widespread problem, reflecting clinical 
practice [6]. Last, the women were seen just once 8 weeks 
after their pregnancy, and we thus have no knowledge of 
the long-term evolution of our population. 
In spi te of these limitations, we feel that our results sup-
port the fact, presented in other studies, that GDM can be 
looked upon as an important metabolic abnormality, 
appearing before, at the same time or after obesity, hyper-
tension and dyslipidaemia, in the development of the meta-
bolic syndrome [8, 11]. As the prevalence of obesity and MS 
are increasing throughout the world, particularly in 
younger subjects [22, 36], more and more young pregnant 
women will present these metabolic disturbances. Recog-
nizing GDM as part of the metabolic syndrome, with ail its 
potential cardiovascular complications, is therefore increas-
ingly important. Because GDM screening is non-systematic 
in many centres, we wish to improve the awareness of these 
high-risk women and we suggest adding obesity, hyperten-
sion and dyslipidaemia to the traditional risk factors used 
for screening. Moreover, every post-partum visit should 
include measures of ail the components of the metabolic 
syndrome and not only glucose intolerance. These meas-
Diabetes Metab 2005;31 :361-369 • www.masson.fr/revues/dm 
ures aim at improving post-partum monitoring to allow 
earlier identification and treatment of ail CVD risk factors. 
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